Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance
Reference number: TA276
Published: 27 March 2013

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix A -matrix of stakeholders

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix A -matrix of stakeholders

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix A -matrix of stakeholders
18 May 2015
(97.62 Kb 28 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 15 May 2015